AstraZeneca (AZN LN) Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond."

AstraZeneca's Q1 2026 results beat expectations on both revenue and adjusted EPS, indicating solid operational performance.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Lloyds (LLOY LN) Q1 2026 (GBP): Statutory Pretax Profit 2.03bln (exp. 1.78bln), NII 3.56bln (prev. 3.29bln Y/Y), EPS 2.4p (prev. 1.7p Y/Y); reiterated guidance

TotalEnergies (TTE FP) Q1 2026 (USD): adj. Net 5.39bln (exp. 4.98bln), Cash Flow 8.6bln (prev. 7.2bln Q/Q), Net income 5.8bln (prev. 2.9bln Q/Q), adj. EBITDA 12.6bln (prev. 10.1bln Q/Q). To continue buybacks.

AstraZeneca (AZN LN) Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond."

Newsquawk Daily European Opening News - 29th April 2026

LG Electronics (066570 KS) Q1 2026 (KRW): Net 815.7bln (exp. 801.1bln), Operating profit 1.67tln, Revenue 23.7tln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

2026 Guidance (reconfirmed)

  • Total Revenue is expected to increase by a mid-to-high single-digit percentage
  • Core EPS is expected to increase by a low double-digit percentage
Context

The reaffirmation of guidance suggests confidence in their growth trajectory, which is favorable for investor sentiment, particularly in the pharmaceuticals sector. This could positively impact AstraZeneca's stock and potentially lift sector peers, given the strong outlook through 2030.

Related headlines

The whole workspace, free to try.

Try it free